10X Genomics Inc

10X Genomics Inc

TXG · NASDAQ · Healthcare / Medical Devices

58.19USD-0.91 (-1.54%)

Price History

Full chart

Market Stats

Previous Close59.10
Open59.50
Day Range56.32 – 59.50
52-Week Range12.80 – 102.81
Volume2.12M
Market Cap10.63B
P/E (TTM)0.00
Forward P/E10000.00
EPS-0.58
Dividend Yield0.00%
Beta1.99
50-Day Avg74.05
200-Day Avg40.33

About

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Serge Saxonov Ph.D.
  • Employees1.18K
  • Headquarters6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260, USA
  • Websitehttps://www.10xgenomics.com

Leadership

  • Dr. Serge Saxonov Ph.D.Co-Founder, CEO & Director · b. 1977
  • Dr. Benjamin J. Hindson Ph.D.Co-Founder, President, Chief Scientific Officer & Director · b. 1975
  • Mr. Adam S. TaichCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · b. 1975
  • Mr. Jim GoodrichChief of Global Operations
  • Mr. Michael Schnall-Levin Ph.D.Founding Scientist & CTO
  • Ms. Cassie CorneauManager of Investor Relations & Strategic Finance
  • Dr. Randy WuGeneral Counsel and Secretary
  • Ms. Mennah MoustafaChief Commercial Officer
  • Mr. Jens DurruthyAssociate Director of Product Management

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue71.08M146.31M245.89M298.85M490.49M516.41M618.73M610.78M642.82M
Growth (%)-+105.83%+68.06%+21.53%+64.13%+5.28%+19.81%-1.28%+5.25%
Cost of Revenue10.56M28.66M61.03M58.47M74.09M120.39M209.41M196.30M198.94M
Gross Profit60.52M117.65M184.86M240.38M416.40M396.02M409.31M414.48M443.88M
Gross Margin85.14%80.41%75.18%80.44%84.89%76.69%66.15%67.86%69.05%
Operating Expense78.90M228.42M213.93M325.70M469.31M563.97M674.64M609.04M554.77M
Operating Income-18.38M-110.76M-29.07M-85.32M-52.91M-167.94M-265.33M-194.56M-110.89M
Operating Margin-25.85%-75.70%-11.82%-28.55%-10.79%-32.52%-42.88%-31.85%-17.25%
EBITDA-13.63M-106.08M-20.89M-513.77M-24.59M-128.49M-205.11M-133.99M3.91M
EBITDA Margin-19.17%-72.50%-8.49%-171.92%-5.01%-24.88%-33.15%-21.94%0.61%
Net Income-18.76M-112.48M-31.25M-542.73M-58.22M-166.00M-255.10M-182.63M-43.54M
Net Income Margin-26.39%-76.88%-12.71%-181.61%-11.87%-32.15%-41.23%-29.90%-6.77%
R&D32.16M47.54M83.10M123.38M211.75M265.67M270.33M264.70M238.63M
R&D as % of Total Revenue45.25%32.49%33.79%41.28%43.17%51.45%43.69%43.34%37.12%
Interest Expense811.00K2.41M3.08M1.68M866.00K476.00K33.00K4.00K0
Interest Expense % of Total Revenue1.14%1.65%1.25%0.56%0.18%0.09%0.01%0.00%0.00%

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets75.61M124.31M605.92M929.34M1.02B1.03B965.14M918.64M1.04B
Total Liabilities188.12M344.30M185.84M190.27M201.26M223.24M224.10M208.50M245.04M
Total Equity-112.51M-219.99M420.08M739.07M817.57M805.74M741.04M710.13M796.33M
Cash47.86M65.08M424.17M663.60M587.45M219.75M359.28M344.07M473.97M
Total Debt10.56M29.68M29.72M62.98M81.98M95.18M95.37M82.61M157.74M
Net Debt-37.30M-35.40M-394.45M-600.63M-505.47M-124.57M-263.91M-261.45M-316.23M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.70M-76.41M34.63M-217.90M-21.37M-33.61M-15.20M6.66M136.05M
Investing Cash Flow-3.76M-6.71M-42.77M-38.39M-106.73M-350.89M133.49M-32.63M-13.44M
Financing Cash Flow20.58M105.37M414.59M468.91M35.30M15.82M13.67M10.91M6.80M
Capital Expenditure3.76M6.71M42.77M38.39M101.28M131.66M49.52M12.39M5.93M
Free Cash Flow-14.46M-83.12M-8.14M-256.29M-122.65M-165.27M-64.72M-5.73M130.12M
Dividends Paid00-------
FCF to OCF135.11%108.78%-23.51%117.62%573.86%491.78%425.88%-85.97%95.64%
Dividend Paid to FCF0.00%0.00%-------

Earnings

Report DateSep 11, 2019Nov 7, 2019Feb 18, 2020May 11, 2020Aug 11, 2020Nov 10, 2020Feb 17, 2021May 5, 2021Aug 4, 2021Nov 3, 2021Feb 16, 2022May 4, 2022Aug 8, 2022Nov 2, 2022Feb 15, 2023May 3, 2023Aug 3, 2023Nov 2, 2023Feb 15, 2024Apr 30, 2024Aug 8, 2024Oct 29, 2024Feb 12, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 12, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-0.11-0.10-0.13-0.13-0.49-0.31-0.07-0.19-0.23-0.21-0.03-0.33-0.30-0.24-0.20-0.16-0.05-0.04-0.36-0.39-0.23-0.26-0.11-0.29-0.35-0.07-0.04-0.06-0.23-0.29
EPS Actual-0.16-0.33-0.07-0.20-0.41-0.25-0.08-0.11-0.11-0.15-0.16-0.14-0.25-0.070.21-0.07-0.14-0.10-0.41-0.200.01-0.02-0.14-0.100.28-0.020.070.07-0.14-
Surprise-45.45%-230.00%46.15%-53.85%16.33%19.35%-14.29%42.11%52.17%28.57%-433.33%57.58%16.67%70.83%205.00%56.25%-180.00%-150.00%-13.89%48.72%104.35%92.31%-27.27%65.52%180.00%71.43%275.00%216.67%39.13%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap10.63B
Enterprise Value10.42B
Trailing P/E0.00
Forward P/E10000.00
Price / Sales17.22
Price / Book13.20
EPS-0.58
Book Value6.34
Revenue (TTM)616.91M
Gross Profit (TTM)432.53M
EBITDA-41.20M
Profit Margin-12.18%
Operating Margin-15.20%
Return on Equity-9.40%
Return on Assets-5.05%
Shares Outstanding120.21M
Shares Float118.19M
Beta1.99
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 18 analystsTarget 77.50
  • Strong Buy
    6
  • Buy
    1
  • Hold
    11

Ownership Breakdown

Institutions
117.64%
Insiders
1.44%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    17.63M13.53%
  • BlackRock Inc
    10.80M8.29%
  • ARK Investment Management LLC
    10.00M7.68%
  • Vanguard Portfolio Management, LLC
    6.98M5.36%
  • Quantinno Capital Management LP
    5.47M4.20%
  • Vanguard Capital Management, LLC
    5.08M3.90%
  • T. Rowe Price Associates, Inc.
    4.54M3.48%
  • Sumitomo Mitsui Trust Group Inc
    4.19M3.22%
  • Amova Asset Management Americas, Inc
    4.19M3.22%
  • Morgan Stanley - Brokerage Accounts
    3.35M2.57%
  • The Goldman Sachs Group Inc
    3.15M2.42%
  • Geode Capital Management, LLC
    3.08M2.37%
  • State Street Corp
    2.80M2.15%
  • Citadel Advisors Llc
    2.78M2.13%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.82M2.93%
  • ARK Innovation ETF
    3.06M2.35%
  • iShares Russell 2000 ETF
    3.03M2.33%
  • Vanguard Small Cap Index
    2.71M2.08%
  • T. Rowe Price New Horizons
    2.65M2.03%
  • ARK Genomic Revolution ETF
    2.46M1.89%

Stock Splits

  • Jul 17, 20061:2